<DOC>
	<DOCNO>NCT01589185</DOCNO>
	<brief_summary>The objective study assess safety , tolerability , pharmacokinetics , pharmacodynamics clinical outcome patient severe pneumonia cause Staphylococcus aureus ( S. aureus ) single intravenous administration KBSA301 addition standard care antibiotic treatment .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Efficacy KBSA301 Severe Pneumonia ( S. Aureus )</brief_title>
	<detailed_description>S. aureus lead cause bloodstream , skin , soft tissue , low respiratory tract infection worldwide . The frequency nosocomial community-acquired S. aureus infection increase steadily year treatment infection become challenge due emergence multi-drug resistant strain ( e.g . methicillin-resistant Staphylococcus aureus ) . S. aureus several virulence factor contribute pathogenesis infection . Amongst , alpha-toxin involved pathogenesis pneumonia , lead apoptosis cell lysis , particular lymphocyte , macrophage , alveolar epithelial cell , pulmonary endothelium , thrombocyte . In spite preventive measure S. aureus infection current medical treatment ( mostly antibiotic therapy , alone combination ) , clear unmet medical need clinic additional treatment option . Passive immunotherapy monoclonal antibody may improve treatment option severe life-threatening infection like cause S. aureus .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Staphylococcal</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adult male female patient ≥ 18 year ≤ 70 year age Severe pneumonia cause S. aureus ( either methicillinresistant methicillinsensitive ) manage ICU APACHE II ≤30 time diagnosis Identification S. aureus Written inform consent provide patient , relative designate trusted person and/or accord local guideline Women child bear potential exclude participation study unless negative pregnancy test baseline course study . Postmenopausal woman females surgically sterilize allow participate . Hypersensitivity excipients prescribed medication Severe neutropenia , lymphoma anticipate chemotherapy Patients longterm tracheostomy Current recent investigational drug ( within 30 day enrollment , 5 halflives investigational compound , whichever longer ) Presence meningitis , endocarditis , osteomyelitis Acquired immune deficiency syndrome ( AIDS ) cluster differentiation 4 ( CD4 ) count &lt; 200 cells/ml Known bronchial obstruction history postobstructive pneumonia . Active primary lung cancer another malignancy metastatic lung Cystic fibrosis , know suspect Pneumocystis jiroveci pneumonia , know suspect active tuberculosis Immunosuppressive therapy Liver function deficiency Moribund clinical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pneumonia</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Staphylococcus aureus</keyword>
</DOC>